254 related articles for article (PubMed ID: 27124592)
1. Genetically modified human CD4(+) T cells can be evaluated in vivo without lethal graft-versus-host disease.
Ali R; Babad J; Follenzi A; Gebe JA; Brehm MA; Nepom GT; Shultz LD; Greiner DL; DiLorenzo TP
Immunology; 2016 Aug; 148(4):339-51. PubMed ID: 27124592
[TBL] [Abstract][Full Text] [Related]
2. Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression.
Brehm MA; Kenney LL; Wiles MV; Low BE; Tisch RM; Burzenski L; Mueller C; Greiner DL; Shultz LD
FASEB J; 2019 Mar; 33(3):3137-3151. PubMed ID: 30383447
[TBL] [Abstract][Full Text] [Related]
3. Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease.
Covassin L; Laning J; Abdi R; Langevin DL; Phillips NE; Shultz LD; Brehm MA
Clin Exp Immunol; 2011 Nov; 166(2):269-80. PubMed ID: 21985373
[TBL] [Abstract][Full Text] [Related]
4. Visualization of the human CD4⁺ T-cell response in humanized HLA-DR4-expressing NOD/Shi-scid/γc(null) (NOG) mice by retrogenic expression of the human TCR gene.
Takahashi T; Katano I; Ito R; Ito M
Biochem Biophys Res Commun; 2015 Jan; 456(1):219-24. PubMed ID: 25462565
[TBL] [Abstract][Full Text] [Related]
5. Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease.
Pino S; Brehm MA; Covassin-Barberis L; King M; Gott B; Chase TH; Wagner J; Burzenski L; Foreman O; Greiner DL; Shultz LD
Methods Mol Biol; 2010; 602():105-17. PubMed ID: 20012395
[TBL] [Abstract][Full Text] [Related]
6. Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity.
Ha SP; Klemen ND; Kinnebrew GH; Brandmaier AG; Marsh J; Hangoc G; Palmer DC; Restifo NP; Cornetta K; Broxmeyer HE; Touloukian CE
J Clin Invest; 2010 Dec; 120(12):4273-88. PubMed ID: 21084750
[TBL] [Abstract][Full Text] [Related]
7. Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice.
Babad J; Mukherjee G; Follenzi A; Ali R; Roep BO; Shultz LD; Santamaria P; Yang OO; Goldstein H; Greiner DL; DiLorenzo TP
Clin Exp Immunol; 2015 Mar; 179(3):398-413. PubMed ID: 25302633
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of graft-versus-host-disease in NOD scid IL-2Rγ(-/-) (NSG) mice by ex vivo modulation of human CD4(+) T cells.
Hilger N; Glaser J; Müller C; Halbich C; Müller A; Schwertassek U; Lehmann J; Ruschpler P; Lange F; Boldt A; Stahl L; Sack U; Oelkrug C; Emmrich F; Fricke S
Cytometry A; 2016 Sep; 89(9):803-15. PubMed ID: 27560708
[TBL] [Abstract][Full Text] [Related]
9. Delayed onset of graft-versus-host disease in immunodeficent human leucocyte antigen-DQ8 transgenic, murine major histocompatibility complex class II-deficient mice repopulated by human peripheral blood mononuclear cells.
Büchner SM; Sliva K; Bonig H; Völker I; Waibler Z; Kirberg J; Schnierle BS
Clin Exp Immunol; 2013 Aug; 173(2):355-64. PubMed ID: 23607364
[TBL] [Abstract][Full Text] [Related]
10. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q
Front Immunol; 2021; 12():686439. PubMed ID: 34616392
[TBL] [Abstract][Full Text] [Related]
11. Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype.
Ali N; Flutter B; Sanchez Rodriguez R; Sharif-Paghaleh E; Barber LD; Lombardi G; Nestle FO
PLoS One; 2012; 7(8):e44219. PubMed ID: 22937164
[TBL] [Abstract][Full Text] [Related]
12. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.
Straetemans T; Coccoris M; Berrevoets C; Treffers-Westerlaken E; Scholten CE; Schipper D; Ten Hagen TL; Debets R
Hum Gene Ther; 2012 Feb; 23(2):187-201. PubMed ID: 21958294
[TBL] [Abstract][Full Text] [Related]
13. Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses.
Yaguchi T; Kobayashi A; Inozume T; Morii K; Nagumo H; Nishio H; Iwata T; Ka Y; Katano I; Ito R; Ito M; Kawakami Y
Cell Mol Immunol; 2018 Nov; 15(11):953-962. PubMed ID: 29151581
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice.
Nervi B; Rettig MP; Ritchey JK; Wang HL; Bauer G; Walker J; Bonyhadi ML; Berenson RJ; Prior JL; Piwnica-Worms D; Nolta JA; DiPersio JF
Exp Hematol; 2007 Dec; 35(12):1823-38. PubMed ID: 17764813
[TBL] [Abstract][Full Text] [Related]
15. Increased risk of lethal graft-versus-host disease-like syndrome after transplantation into NOD/SCID mice of human mobilized peripheral blood stem cells, as compared to bone marrow or cord blood.
Gorin NC; Piantadosi S; Stull M; Bonte H; Wingard JR; Civin C
J Hematother Stem Cell Res; 2002 Apr; 11(2):277-92. PubMed ID: 11983099
[TBL] [Abstract][Full Text] [Related]
16. Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model.
Nakauchi Y; Yamazaki S; Napier SC; Usui J; Ota Y; Takahashi S; Watanabe N; Nakauchi H
Exp Hematol; 2015 Feb; 43(2):79-88.e1-4. PubMed ID: 25448490
[TBL] [Abstract][Full Text] [Related]
17. Comparison of three humanized mouse models for adoptive T cell transfer.
Volk A; Hartmann S; Muik A; Geiss Y; Königs C; Dietrich U; von Laer D; Kimpel J
J Gene Med; 2012 Aug; 14(8):540-8. PubMed ID: 22847974
[TBL] [Abstract][Full Text] [Related]
18. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.
Cho HI; Kim UH; Shin AR; Won JN; Lee HJ; Sohn HJ; Kim TG
Br J Cancer; 2018 Feb; 118(4):534-545. PubMed ID: 29360818
[TBL] [Abstract][Full Text] [Related]
19. T cell receptor gene-modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft-versus-host disease.
Okada S; Muraoka D; Yasui K; Tawara I; Kawamura A; Okamoto S; Mineno J; Seo N; Shiku H; Eguchi S; Ikeda H
Cancer Sci; 2023 Nov; 114(11):4172-4183. PubMed ID: 37675556
[TBL] [Abstract][Full Text] [Related]
20. Phytohemagglutinin-activated human T cells induce lethal graft-versus-host disease in cyclophosphamide and anti-CD122 conditioned NOD/SCID mice.
Hu Y; Gu Y; Cui Q; Fu H; Sheng L; Wu K; Liu L; Fu S; Yu X; Huang H
Ann Hematol; 2012 Nov; 91(11):1803-12. PubMed ID: 22699803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
